• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Research Brief on 1-(5-Bromo-2-iodothiophen-3-yl)ethan-1-one (CAS: 2763758-95-6) in Chemical Biology and Pharmaceutical Applications

1-(5-Bromo-2-iodothiophen-3-yl)ethan-1-one (CAS: 2763758-95-6) is a halogenated thiophene derivative that has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile reactivity and potential as a building block for drug discovery. This compound features both bromo and iodo substituents on a thiophene ring, making it a valuable intermediate for cross-coupling reactions, such as Suzuki-Miyaura and Sonogashira couplings, which are pivotal in the synthesis of complex bioactive molecules.

Recent studies have highlighted the role of 1-(5-Bromo-2-iodothiophen-3-yl)ethan-1-one in the development of novel kinase inhibitors and antiviral agents. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of thiophene-based analogs that exhibit potent inhibitory activity against EGFR (epidermal growth factor receptor) mutants associated with non-small cell lung cancer. The compound's unique electronic properties, conferred by the halogen atoms, enhance its binding affinity to target proteins, thereby improving therapeutic efficacy.

In addition to its applications in oncology, this compound has been explored in the context of infectious diseases. A preprint from BioRxiv (2024) reported its incorporation into a series of thiophene-carboxamide derivatives, which showed promising activity against SARS-CoV-2 viral proteases. The researchers attributed this activity to the compound's ability to disrupt viral replication cycles through selective inhibition of key enzymatic processes.

From a synthetic chemistry perspective, 1-(5-Bromo-2-iodothiophen-3-yl)ethan-1-one offers advantages in regioselective functionalization. A recent Organic Letters publication (2024) detailed a one-pot sequential cross-coupling strategy using this compound to generate diverse thiophene scaffolds with high yields and minimal byproducts. This methodological advancement underscores its potential for streamlining the synthesis of structurally complex pharmaceuticals.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of derivatives derived from this scaffold. Current research efforts, as noted in a 2024 review in Chemical Science, are focused on modifying the thiophene core to improve metabolic stability and reduce off-target effects. Computational modeling studies suggest that strategic substitutions at the 4-position of the thiophene ring could enhance drug-like characteristics while retaining bioactivity.

In conclusion, 1-(5-Bromo-2-iodothiophen-3-yl)ethan-1-one (CAS: 2763758-95-6) represents a chemically tractable and biologically relevant scaffold with broad applications in medicinal chemistry. Ongoing research continues to uncover its potential in addressing unmet medical needs, particularly in oncology and antiviral therapy. Future directions may include the exploration of its utility in targeted protein degradation and PROTAC development, leveraging its dual functionality for innovative therapeutic modalities.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)